Removing the central mole versus medicine alone in halo nevus with vitiligo
Compares removing the central mole with medicine alone in people with halo nevus and vitiligo.
Plain-language title generated from the registry record
Registry title: Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study
Key facts
- Where
- Xi'an, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with halo nevus and non-segmental vitiligo. It compares removing the central nevus plus medication with medication only.
- Age
- 6 to 45 years
- Sex
- All sexes can join.
- Disease stage
- Halo nevus with non-segmental vitiligo covering 2% of body surface area or less (not counting hands and feet). The central nevus must be confirmed benign.
- Earlier treatment
- No hormonal medicines, immune-modifying medicines or light therapy (phototherapy) in the past 1 month.
Main reasons for not taking part
- History of keloid or thick scar formation
- Other autoimmune diseases, such as hyperthyroidism
- Pregnant or breastfeeding women
- Allergy to anesthetic agents or their ingredients
- Major illness of the hormones, mind, blood, liver, kidney, heart or brain, or severe infection
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 45 years old?
Source: NCT07307534, who can take part
Where in China
- Xijing hospitalXi'an, ChinaContact: Zhe JianNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT07307534
- Record updated
- 15 January 2026
- Original description
This clinical trial aims to compare the efficacy and safety of central nevus removal versus conservative treatment in patients with halo nevus accompanied by non-segmental vitiligo. It is a single-center, prospective, randomized controlled trial involving 60 participants aged 6 to 45 years, who will be randomly assigned to either the nevus removal group or the conservative treatment group. The removal group will undergo surgical or laser excision of the central nevus followed by medication, while the conservative group will receive medication only. Both groups will be followed for 6 months. Outcomes include repigmentation assessment using vitiligo scoring indices, quality of life measures, and serial serum cytokine profiling. The study seeks to provide high-level evidence to guide clinical management of halo nevus with vitiligo. Key points:Read full original descriptionShow less
Central Nevus Removal Versus Conservative Treatment for Halo Nevus With Vitiligo: A Prospective Randomized Controlled Trial
This clinical trial aims to compare the efficacy and safety of central nevus removal versus conservative treatment in patients with halo nevus accompanied by non-segmental vitiligo. It is a single-center, prospective, randomized controlled trial involving 60 participants aged 6 to 45 years, who will be randomly assigned to either the nevus removal group or the conservative treatment group. The removal group will undergo surgical or laser excision of the central nevus followed by medication, while the conservative group will receive medication only. Both groups will be followed for 6 months. Outcomes include repigmentation assessment using vitiligo scoring indices, quality of life measures, and serial serum cytokine profiling. The study seeks to provide high-level evidence to guide clinical management of halo nevus with vitiligo. Key points:
1. For patients with halo nevus accompanied by non-segmental vitiligo. 2. For patients aged 6 to 45 years. 3. Compares nevus excision and conservative treatment. 4. Follows participants for 6 months. 5. Focuses on effectiveness and safety.
Inclusion: Patients with halo nevus accompanied by non-segmental vitiligo, with BSA ≤2% (excluding acral regions); Central nevus confirmed as benign melanocytic nevus through clinical observation and dermatoscope; Age 6 to 45 years, regardless of gender ④ Physically able to tolerate surgery and local anesthesia.
Exclusion: History of keloid formation or hypertrophic scarring (to avoid abnormal hyperplasia at the operative site and interference with repigmentation assessment); Other autoimmune diseases (e.g., hyperthyroidism); Patients with significant endocrine disorders, psychiatric conditions, hematologic diseases, hepatic/renal disorders, cardiovascular/cerebrovascular diseases, severe infections, or other major systemic illnesses; Use of hormonal medications, immunomodulators, or phototherapy within the past 1 month ⑤ Pregnant or lactating women ⑥ Allergy to anesthetic agents or excipients; Poor psychological status or compliance, unable to cooperate with postoperative follow-up or care ⑧ Concurrent conditions requiring other treatments that may interfere with the study observations.